

Be a Global Specialty Pharma, competing in the global arena with original and innovative new drugs

Issues and Awareness of Business Environment

Issues Facing Healthcare

- Complex and advanced healthcare needs
- Aging population
- Improvement in access to healthcare

Issues Facing Society

- Harmonious coexistence of society and businesses
- Mutual prosperity of employees and businesses
- Diversity enhancement

Business Environment

- Progression of healthcare cost reduction measures around the world
- Tighter regulatory controls stemming from fundamental review of the NHI drug pricing system in Japan
- Increasing complexity of target diseases for drug discovery
- Decreased success rates of drug discovery
- Prolonged period/rising costs of new drug development
- Globally increasing competition
- Increasing opportunity to achieve drug discovery innovations
- Expansion into the global market

Relevant SDGs



Capital to be Input

(2022.3)



Financial capital

A strong financial base that supports sustained drug discovery

Total capital: ¥661.6 billion

Ratio of equity attributable to owners of the parent company: 88.7%



Manufacturing capital

A manufacturing base that ensures stable supply of high-quality pharmaceutical products

Capital investment: ¥9.3 billion

Manufacturing centers: 2



Intellectual capital

R&D abilities based on ONO's unique drug discovery approach and open innovation

R&D costs: ¥75.8 billion

R&D cost-to-revenue ratio: 21%



Human capital

Providing a challenger culture and opportunities for personal growth

Number of employees (consolidated): 3,687

Total training time: 187,357 hours



Social capital

Various forms of partnership to create sustainable society

Number of drug discovery alliances and joint research projects with universities, biopharmaceutical companies, etc.

More than 200 (Japan and overseas)



Natural capital

Eco VISION 2050 and environmental management

Energy consumption: 99,438 MWh

Water resource consumption (water intake): 185 thousand m³

Corporate Philosophy

Dedicated to the Fight against Disease and Pain

Focusing limited management resources into drug discovery and development

In-house Drug Discovery

We focus on unique bioactivity, finding diseases against which drug candidates are most potentially effective, and taking up the challenge of discovering innovative drugs

Licensing Activities

We are promoting expansion of our development pipeline and global marketing of new drugs we develop

Four Growth Strategies

Maximization of product value
- From a patient-centered perspective -

Reinforcement of pipelines and acceleration of global development

Realization of direct sales in the US and Europe

Expansion of business domains



Expansion of indicated tumors:
OPDIVO Intravenous Infusion

Multiple global development products

Providing Products to a Broad Range of Areas

Start of clinical trials in the US:
Tirabrutinib

Expansion of our business domain:
Sleep supplement REMWELL



Material Issues (Important CSR Issues) → P25-

Value Creation → P25-

- Creation of Innovative Drugs
- Pipeline Expansion
- Maximization of Product Value
- Realization of Direct Sales in the US and Europe
- Expansion of Business Domains

Foundation for Value Creation → P39-

- Corporate Transformation through Digital & IT
- Strengthening of Financial Capital
- Expansion of Human Capital
- Intellectual Property Strategies
- Open Innovation
- Promotion of Diverse Partnerships

Value Preservation → P61-

- Assurance of Product Reliability and Safety
- Stable Supply of Products
- Protection of Environment
- Respect for Human Rights
- Thorough Compliance
- Supply Chain Management

Strengthening of Corporate Governance → P91-

Policy for Sustainable Management Contributing to People's Health

(FY2021 results)



Economic Value

- Stable revenue from new drug creation and additional indications (revenue from sales: 361.4 billion yen)
- Stable return of profits to shareholders through sustainable growth (Cash dividend per share: 56.00 yen, payout ratio: 34.5%)



Societal Value

- Creation of innovative drugs
- Stable supply of high-quality drugs
- Increasing access to medical care
- Employment of people with disabilities at 2.38% (0.21% increase over the previous year)
- Cooperation with the local community (e.g., through a cooperation agreement with the Osaka Prefectural Government)
- Diverse talents
95.9% retention rate of female employees, 487 employees hired mid-career (up 107 from FY2017)



Environmental Value

- Reduction of greenhouse gas emissions (20.9% for Scope 1 + 2 and 33.7% for Scope 3, both compared to FY2017)
- Increase in renewable energy use as a percentage of total electricity consumption: 17% (previous FY was 13.2%)
- Reduction of water consumption (reduction of water intake vs. FY2020: 10.7%)
- Maintained 1% or less for the final landfill disposal of industrial waste as a percentage of all industrial waste (0.04%)
- Use of environmentally friendly packaging (ex. Change from plastic to paper)